Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for ?6 million on September 20, 2022. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year. Pierre-Olivier Mahieu and Sophie Rutten of Allen & Overy LLP (Brussels) acted as legal advisor to Celyad Oncology SA (ENXTBR:CYAD).
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2905 EUR | -5.68% |
|
-3.17% | -25.51% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.51% | 13.63M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+33.93% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA for ?6 million.